ResearcherSeoul National UniversityActive in the last 2 years
Chang-Sup Lim
Matched on ORCID iD 0000-0002-2349-9647; OpenAlex author ID A5065503124. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 49
2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 6
- Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized contro… Co-author DOI 10.1186/s12885-026-15639-6↗
- Changing Clinical Meaning of Resection Margin Status According to the Treatment Paradigm and the Potential Role of Perioperative Radiotherapy for Patients with… Co-author DOI 10.1245/s10434-025-17389-4↗
- Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Japanese joint cohort and the SEER database. Co-author DOI 10.1002/jhbp.1316↗
- Development of Nomograms for Predicting Prognosis of Pancreatic Cancer after Pancreatectomy: A Multicenter Study. Co-author DOI 10.3390/biomedicines10061341↗
- Development and External Validation of Survival Prediction Model for Pancreatic Cancer Using Two Nationwide Databases: Surveillance, Epidemiology and End Resul… Co-author DOI 10.5009/gnl20306↗
- The Implication of Cytogenetic Alterations in Pancreatic Ductal Adenocarcinoma and Intraductal Papillary Mucinous Neoplasm Identified by Fluorescence In Situ H… Co-author DOI 10.5009/gnl19087↗
Closest collaborators
The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Wooil Kwon · 5 shared papers, 2020–2026 · strength 0.77
- Paper Changing Clinical Meaning of Resection Margin Status According to the Treatment Paradigm and the Potential Role of Peri… DOI 10.1245/s10434-025-17389-4↗
- Paper Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, mul… DOI 10.1186/s12885-026-15639-6↗
- Paper Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Jap… DOI 10.1002/jhbp.1316↗
- Yoo‐Seok Yoon · 4 shared papers, 2021–2026 · strength 0.65
- Paper Changing Clinical Meaning of Resection Margin Status According to the Treatment Paradigm and the Potential Role of Peri… DOI 10.1245/s10434-025-17389-4↗
- Paper Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, mul… DOI 10.1186/s12885-026-15639-6↗
- Paper Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Jap… DOI 10.1002/jhbp.1316↗
- Jin‐Young Jang · 4 shared papers, 2020–2025 · strength 0.58
- Paper Changing Clinical Meaning of Resection Margin Status According to the Treatment Paradigm and the Potential Role of Peri… DOI 10.1245/s10434-025-17389-4↗
- Paper Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Jap… DOI 10.1002/jhbp.1316↗
- Paper The Implication of Cytogenetic Alterations in Pancreatic Ductal Adenocarcinoma and Intraductal Papillary Mucinous Neopl… DOI 10.5009/gnl19087↗
- In Woong Han · 4 shared papers, 2021–2026 · strength 0.56
- Paper Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, mul… DOI 10.1186/s12885-026-15639-6↗
- Paper Development of Nomograms for Predicting Prognosis of Pancreatic Cancer after Pancreatectomy: A Multicenter Study. DOI 10.3390/biomedicines10061341↗
- Paper Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Jap… DOI 10.1002/jhbp.1316↗
- Hye‐Sol Jung · 2 shared papers, 2025–2026 · strength 0.44
- Paper Changing Clinical Meaning of Resection Margin Status According to the Treatment Paradigm and the Potential Role of Peri… DOI 10.1245/s10434-025-17389-4↗
- Paper Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, mul… DOI 10.1186/s12885-026-15639-6↗
- Jin Seok Heo · 3 shared papers, 2021–2023 · strength 0.37
- Paper Development of Nomograms for Predicting Prognosis of Pancreatic Cancer after Pancreatectomy: A Multicenter Study. DOI 10.3390/biomedicines10061341↗
- Paper Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Jap… DOI 10.1002/jhbp.1316↗
- Paper Development and External Validation of Survival Prediction Model for Pancreatic Cancer Using Two Nationwide Databases: … DOI 10.5009/gnl20306↗
- Sang Hyun Shin · 2 shared papers, 2021–2022 · strength 0.25
- Paper Development of Nomograms for Predicting Prognosis of Pancreatic Cancer after Pancreatectomy: A Multicenter Study. DOI 10.3390/biomedicines10061341↗
- Paper Development and External Validation of Survival Prediction Model for Pancreatic Cancer Using Two Nationwide Databases: … DOI 10.5009/gnl20306↗
- Won‐Gun Yun · 1 shared paper, 2025 · strength 0.25
- Yoon Soo Chae · 1 shared paper, 2025 · strength 0.25
- Seungyeoun Lee · 2 shared papers, 2021–2023 · strength 0.22
- Taesung Park · 2 shared papers, 2021–2023 · strength 0.22
- Sang‐Jae Park · 2 shared papers, 2021–2023 · strength 0.22
- Julian Choi · 1 shared paper, 2026 · strength 0.19
- Jin-Young Jang · 1 shared paper, 2026 · strength 0.19
- Ju Won Kim · 1 shared paper, 2026 · strength 0.19
- Keun Soo Ahn · 1 shared paper, 2026 · strength 0.19
- Hyung Il Seo · 1 shared paper, 2026 · strength 0.19
- Hei‐Cheul Jeung · 1 shared paper, 2026 · strength 0.19
- Do‐Youn Oh · 1 shared paper, 2026 · strength 0.19
- Jai Hoon Yoon · 1 shared paper, 2026 · strength 0.19
- Tae Ho Hong · 1 shared paper, 2026 · strength 0.19
- So Jeong Yoon · 1 shared paper, 2022 · strength 0.16
- Jaewoo Kwon · 1 shared paper, 2022 · strength 0.16
- Woohyun Jung · 1 shared paper, 2022 · strength 0.16
- Teiichi Sugiura · 1 shared paper, 2023 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.